Fig. 1: RAS/BRAF mutations are enriched in extramedullary disease (EMD). | Blood Cancer Journal

Fig. 1: RAS/BRAF mutations are enriched in extramedullary disease (EMD).

From: Integration of clinical outcomes and molecular features in extramedullary disease in multiple myeloma

Fig. 1

A Study overview of myeloma patients with mutational testing and EMD development characterized by imaging. B Overall survival (OS) of EMD patients (n = 114) versus non-EMD patients (n = 414) demonstrated a median OS of 5.3 years vs 12.1 years (p < 0.001). C Mutational profile of 24 EMD and 7 paired bone marrow (BM) samples. Each column represents a patient sample, and the different rows highlight the mutated genes: 11 patients harbored an NRAS mutation, 7 had a KRAS mutation and 5 patients had a BRAF mutation with 1 patient harboring both BRAF and KRAS mutations.

Back to article page